HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M400239-JLR200v1 45/11/2000    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bellamine, A. Articles by Waterman, M. R. Search for Related Content PubMed PubMed Citation Articles by Bellamine, A. Articles by Waterman, M. R. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 45, 2000-2007, November 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology

Aouatef Bellamine¹, Galina I. Lepesheva and Michael R. Waterman

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232-0146

¹ To whom correspondence should be addressed. e-mail: aouatef.bellamine{at}vanderbilt.edu

14-Demethylase (CYP51) is a key enzyme in all sterol biosynthetic pathways (animals, fungi, plants, protists, and some bacteria), catalyzing the removal of the C-14 methyl group following cyclization of squalene. Based on mutations found in CYP51 genes from Candida albicans azole-resistant isolates obtained after fluconazole treatment of fungal infections, and using site-directed mutagenesis, we have found that fluconazole binding and substrate metabolism vary among three different CYP51 isoforms: human, fungal, and mycobacterial. In C. albicans, the Y132H mutant from isolates shows no effect on fluconazole binding, whereas the F145L mutant results in a 5-fold increase in its IC₅₀ for fluconazole, suggesting that F145 (conserved only in fungal 14-demethylases) interacts with this azole. In C. albicans, F145L accounts, in part, for the difference in fluconazole sensitivity reported between mammals and fungi, providing a basis for treatment of fungal infections. The C. albicans Y132H and human Y145H CYP51 mutants show essentially no effect on substrate metabolism, but the Mycobacterium tuberculosis F89H CYP51 mutant loses both its substrate binding and metabolism.

Because these three residues align in the three isoforms, the results indicate that their active sites contain important structural differences, and further emphasize that fluconazole and substrate binding are uncoupled properties.

Abbreviations: 14DM/CYP51, cytochrome P450 sterol 14-demethylase; 24M-DHL, 24-methylene dihydrolanosterol; ATCC, American Type Culture Collection; CA, Candida albicans; DHL, 24,25-dihydrolanosterol; DLPC, dilauryl-L--phosphatidylcholine; H, human; MT, Mycobacterium tuberculosis

Supplementary key words Candida albicans, human • inhibitor binding • Mycobacterium tuberculosis • substrate metabolism

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. I. Lepesheva, H.-W. Park, T. Y. Hargrove, B. Vanhollebeke, Z. Wawrzak, J. M. Harp, M. Sundaramoorthy, W. D. Nes, E. Pays, M. Chaudhuri, et al. Crystal Structures of Trypanosoma brucei Sterol 14{alpha}-Demethylase and Implications for Selective Treatment of Human Infections J. Biol. Chem., January 15, 2010; 285(3): 1773 - 1780. [Abstract] [Full Text] [PDF]

				A. G. S. Warrilow, C. J. Jackson, J. E. Parker, T. H. Marczylo, D. E. Kelly, D. C. Lamb, and S. L. Kelly Identification, Characterization, and Azole-Binding Properties of Mycobacterium smegmatis CYP164A2, a Homolog of ML2088, the Sole Cytochrome P450 Gene of Mycobacterium leprae Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1157 - 1164. [Abstract] [Full Text] [PDF]

				J. E. Parker, M. Merkamm, N. J. Manning, D. Pompon, S. L. Kelly, and D. E. Kelly Differential Azole Antifungal Efficacies Contrasted Using a Saccharomyces cerevisiae Strain Humanized for Sterol 14{alpha}-Demethylase at the Homologous Locus Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3597 - 3603. [Abstract] [Full Text] [PDF]

				A. N. Eddine, J. P. von Kries, M. V. Podust, T. Warrier, S. H. E. Kaufmann, and L. M. Podust X-ray Structure of 4,4'-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14{alpha}-Demethylase (CYP51) J. Biol. Chem., May 30, 2008; 283(22): 15152 - 15159. [Abstract] [Full Text] [PDF]

				R. E Summons, A. S Bradley, L. L Jahnke, and J. R Waldbauer Steroids, triterpenoids and molecular oxygen Phil Trans R Soc B, June 29, 2006; 361(1470): 951 - 968. [Abstract] [Full Text] [PDF]

				M. Kudo, M. Ohi, Y. Aoyama, Y. Nitahara, S.-K. Chung, and Y. Yoshida Effects of Y132H and F145L Substitutions on the Activity, Azole Resistance and Spectral Properties of Candida albicans Sterol 14-Demethylase P450 (CYP51): A Live Example Showing the Selection of Altered P450 through Interaction with Environmental Compounds J. Biochem., May 1, 2005; 137(5): 625 - 632. [Abstract] [Full Text] [PDF]

				K. Matsuura, S. Yoshioka, T. Tosha, H. Hori, K. Ishimori, T. Kitagawa, I. Morishima, N. Kagawa, and M. R. Waterman Structural Diversities of Active Site in Clinical Azole-bound Forms between Sterol 14{alpha}-Demethylases (CYP51s) from Human and Mycobacterium tuberculosis J. Biol. Chem., March 11, 2005; 280(10): 9088 - 9096. [Abstract] [Full Text] [PDF]